These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38431830)

  • 1. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 3: Alleviation of hypoxia, muscle-wasting, and modulation of redox functions in amyotrophic lateral sclerosis.
    Li R; Han X; Wang Q; Wang C; Jing W; Zhang H; Wang J; Pan W
    Int J Clin Pharmacol Ther; 2024 Apr; 62(4):169-177. PubMed ID: 38431830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 1: Biogenic components and identification of targets and signaling pathways in amyotrophic lateral sclerosis patients.
    Lin J; Wang J; Wang C; Shan Y; Jing W; Fei Z; Pan W
    Int J Clin Pharmacol Ther; 2024 Apr; 62(4):155-161. PubMed ID: 38239147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 2: Modulation of hypoxia, redox status, and mitochondrial protection in a neuroblastoma cell line, SH-SY5Y.
    Yuan W; Lin J; Wang J; Wang C; Shan Y; Jing W; Fei Z; Pan W
    Int J Clin Pharmacol Ther; 2024 Apr; 62(4):162-168. PubMed ID: 38431829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyotrophic Lateral Sclerosis Symptom Score in Integrative Treatments (ALS-SSIT) for Evaluating Therapeutic Effect of Traditional Chinese Medicine: A Prospective Study.
    Zheng X; Schröder J; Sima D; Wang M; Wang Q; Pan W
    Comput Math Methods Med; 2022; 2022():7594481. PubMed ID: 35469217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
    Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
    Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
    Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
    Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
    de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial.
    Kim S; Yang M; Ku B; Cha E; Seo W; Son I; Kang H; Kim D; Song B; Yang CS; Kim S
    J Ethnopharmacol; 2023 Oct; 315():116670. PubMed ID: 37257710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
    Oki R; Izumi Y; Fujita K; Miyamoto R; Nodera H; Sato Y; Sakaguchi S; Nokihara H; Kanai K; Tsunemi T; Hattori N; Hatanaka Y; Sonoo M; Atsuta N; Sobue G; Shimizu T; Shibuya K; Ikeda K; Kano O; Nishinaka K; Kojima Y; Oda M; Komai K; Kikuchi H; Kohara N; Urushitani M; Nakayama Y; Ito H; Nagai M; Nishiyama K; Kuzume D; Shimohama S; Shimohata T; Abe K; Ishihara T; Onodera O; Isose S; Araki N; Morita M; Noda K; Toda T; Maruyama H; Furuya H; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R;
    JAMA Neurol; 2022 Jun; 79(6):575-583. PubMed ID: 35532908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
    Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
    Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
    PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plaster-The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial.
    Schröder S; Wang M; Sima D; Schröder J; Zhu X; Zheng X; Liu L; Li T; Wang Q; Friedemann T; Liu T; Pan W
    Front Neurol; 2022; 13():990802. PubMed ID: 36324375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
    Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
    Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.